East China Normal University and Aurisco Pharmaceutical Co., Ltd. jointly inaugurated AI-Driven Oligonucleotide Drugs Discovery Laboratory. The signing and inauguration ceremony of the AI-Driven Oligonucleotide Drugs Discovery Joint Laboratory was held at East China Normal University's Putuo Campus on March 11, 2025.

The establishment of the AI-Powered Oligonucleotide Drugs Discovery Joint Laboratory aims to revolutionize therapeutic development targeting (though not restricted to) metabolic disorders including obesity, aging-related pathologies, and neurodegenerative diseases such as Alzheimer's. By integrating artificial intelligence throughout the Oligonucleotide Drugs discovery pipeline, this initiative seeks to forge an innovation hub for next-generation RNA-based therapeutics.

Attendees of the Joint Laboratory Inauguration Ceremony‌
The signing and unveiling ceremony was attended by the following distinguished participants:
From East China Normal University (ECNU):‌
Qian Xuhong‌, President of ECNU and Academician of the Chinese Academy of Engineering ‌
Shi Guoyue‌, Vice President of ECNU ‌
Yang Haibo‌, Director of the Office of Science and Technology ‌
Li Honglin‌, Dean of the School of Pharmacy
From Aurisco Pharmaceutical Co., Ltd.:
Peng Zhien‌, Chairman of the Board ‌
Dr. Li Jinliang‌, Board Member